mounjaro tirzepatide news today september 2025 and Wegovy: Price Changes Coming In adults with obesity but

Description

FDA-approved in March, the new dose showed average weight loss of approximately 21% at 72 weeks in the phase 3 STEP UP trial

When the medication handles the intense cravings, you can focus on portion control and nutritional quality

People with drug abuse are also at an increased risk of experiencing withdrawal symptoms

Side Effects and Safety: What to Expect Both semaglutide and tirzepatide share common GLP-1 class side effects, primarily gastrointestinal: nausea, vomiting, diarrhea, or constipation that typically emerge during dose escalation and diminish as your body adjusts

The rate of subsequent weight regain depends on your diet quality, exercise consistency, and metabolic set point, making lifestyle habits established during treatment critical